Rethinking the INN system for therapeutic antibodies

@inproceedings{Pottier2017RethinkingTI,
  title={Rethinking the INN system for therapeutic antibodies},
  author={J{\'e}r{\'e}my Pottier and Romane Chastang and Christophe Dumet and Herv{\'e} Watier},
  booktitle={mAbs},
  year={2017}
}
In the context of a possible revision of the International Nonproprietary Names (INN) system of recombinant monoclonal antibodies, which is saturated, we propose several avenues of reflection driven by the primary goal of the INN, information of health-care professionals. Clinical considerations argue for an abandon of the substems A (target category) and B (origin category), which lengthen the INN without real added-value. On the contrary, new substems or suffixes are required to alert on the… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

References

Publications referenced by this paper.
Showing 1-10 of 28 references

Modifications in the IgG4 Fc portion of therapeutics in patents: opportunities for a twisting IgG subclass

J Pottier, H Watier, V. Gouilleux-Gruart
Submitted • 2016
View 3 Excerpts
Highly Influenced

confor - mation of the human immunoglobulin G 2 hinge imparts superagonistic properties to immunostimulatory anticancer antibod

AL White, Chan HTC, +6 authors ME Polak
Cancer Cell • 2016

Ocular abnormalities in patients treated with a novel anti-GD2 monoclonal antibody, hu14.18K322A.

Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus • 2015
View 1 Excerpt

Similar Papers

Loading similar papers…